A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorShanghai Zhongshan Hospital
About this trial
In recent years, immunotherapy has made significant progress in the treatment of lung cancer, especially immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies) against non-small cell lung cancer (NSCLC). However, there are significant individual differences in patient response to treatment. Studies have shown that sleep disorders may affect the function of the immune system, thereby affecting tumor progression and treatment response. Therefore, the aim of this study was to evaluate the impact of sleep disturbances on lung cancer patients receiving immunotherapy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Patients with newly diagnosed primary lung cancer (confirmed histopathologically or cytologically) were enrolled at Zhong shan hospital fromJune 2025
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
PSQI
Other interventionProspective observational cohort study: Cohort o: Stratified according to baseline sleep disorder severity (PSQI score ≥7 vs. \<7).
PQSI
Other interventionPQSI-Sleep quality assessment scale
Treatment groups
350 Participants
are divided into 1 treatment groupGroup A: lung cancer-sleep disorders2 interventions
Trial outcomes
Primary outcomes
1
pCR
Pathological complete response (pCR)
Time frame
From enrollment to the end of treatment at two years"Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: